Core Insights - NorthStrive Biosciences, Inc. has filed ten new U.S. patent applications to expand its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, focusing on muscle growth and weight return in animals [1][2]. Group 1: Patent Applications Overview - The ten patent applications consist of five covering EL-22 and five covering EL-32, applicable across various farmed animal categories including livestock, aquaculture, and poultry [2]. - Two applications specifically address the use of EL-22 and EL-32 as non-feed additive supplements to promote muscle tissue growth and increase muscle weight return per animal [3]. Group 2: Environmental and Health Benefits - Additional applications aim to utilize EL-22 and EL-32 for reducing gaseous emissions in livestock, which could lower environmental impact and mitigate risks associated with ruminal tympany [4]. - In aquaculture, applications have been filed to promote muscle growth in aquatic species, potentially reducing the time to reach commercially viable sizes and lowering energy costs [5]. - Further aquaculture applications focus on emissions reduction to help mitigate eutrophic conditions [6]. Group 3: Poultry Applications - The final set of applications pertains to the use of EL-22 and EL-32 in poultry, aimed at enhancing muscle growth and improving muscle yield per bird within standard growth timelines [7]. Company Background - NorthStrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., concentrating on developing advanced aesthetic medicines, with its lead asset, EL-22, designed to address muscle preservation during weight loss treatments [8].

Core Viewpoint - Intellia Therapeutics, Inc. is set to host a conference call on February 26, 2026, to discuss its fourth quarter and full-year 2025 financial results and business updates [1]. Group 1: Company Overview - Intellia Therapeutics is a leading clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine [3]. - The company aims to develop novel, first-in-class medicines that address significant unmet medical needs and advance treatment paradigms for patients [3]. - Intellia is expanding its CRISPR-based platform with novel editing and delivery technologies to harness the full potential of gene editing [3]. Group 2: Conference Call Details - The conference call will take place at 8 a.m. ET on February 26, 2026 [1]. - U.S. callers can join the teleconference by dialing 1-833-316-0545, while international callers should dial 1-412-317-5726 [2]. - A replay of the call will be available for approximately 90 days on the Events page of Intellia's website [2].

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of $926 million as of December 31, 2025 and ...

Core Insights - DT Midstream, Inc. reported a strong financial performance for the fourth quarter and full year of 2025, achieving record results with a 17% year-over-year growth in Adjusted EBITDA [3][7]. Financial Performance - Fourth quarter 2025 reported net income was $111 million, or $1.08 per diluted share, with Operating Earnings also at $111 million [1]. - Full year 2025 reported net income was $441 million, or $4.30 per diluted share, with Operating Earnings matching this figure [2]. - Adjusted EBITDA for the fourth quarter was $293 million, while for the full year it reached $1.138 billion, reflecting a 17% increase from 2024 [2][7]. Business Strategy and Growth - The company successfully integrated its Midwest pipelines and completed key organic growth projects ahead of schedule and on budget, positioning itself to meet increasing demand [3]. - The organic project backlog increased by approximately 50% to $3.4 billion over the next five years, with pipeline projects making up 75% of this backlog [8]. - Adjusted EBITDA guidance for 2026 is projected to be between $1.155 billion and $1.225 billion, indicating a 6% annual growth from the original 2025 guidance [4]. Dividend and Investment Decisions - The company announced a 7% increase in dividends from the fourth quarter of 2025 to $0.88 per share, payable on April 15, 2026 [8]. - Final investment decisions were reached on two pipeline projects, including an expansion of Viking Gas Transmission [7][8].

Core Viewpoint - BrainsWay has entered into a strategic equity financing agreement with BrainStim Health Inc. to enhance access to mental health care through investments in innovative clinical service platforms [1][2] Group 1: Investment Details - BrainsWay will initially invest $1.0 million in BrainStim, with the potential for an additional $1.5 million based on milestones, acquiring a minority position through preferred, annually compounding securities [1] - This investment marks BrainsWay's fifth minority-stake investment in growth-oriented clinical service platforms, aligning with its strategic initiative to expand access to advanced mental health interventions [2] Group 2: Company Background - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [4] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and is committed to advancing its clinical applications [4] Group 3: BrainStim Overview - BrainStim focuses on delivering effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression, particularly for veterans and first responders [5] - The practice employs a team of board-certified psychiatrists and advanced psychiatric nurse practitioners to provide cutting-edge treatment options [5]

On 19 February 2026, AB Akola Group held an investor webinar, where the company's Deputy CEO for Finance and Investments Mažvydas Šileika presented the financial results for the 6 months of the 2025/2026 financial year. The recording of the webinar is available on Nasdaq’s YouTube account: https://youtu.be/vr1pFEOkIHQ?si=uWHqxS-VYYVNI5YB Link to the presentation demonstrated at the webinar: https://www.akolagroup.lt/wp-content/uploads/2026/02/260219_AKOLA_6M_webinar_M.Sileika_final-1.pdf For more informatio ...

VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- One Bullion Ltd. (“One Bullion” or the “Company”) (TSXV: OBUL), a gold exploration company holding complete ownership of three highly prospective mining areas in Botswana, today announced that management will host a booth at PDAC 2026, The World’s Premier Mineral Exploration & Mining Convention, taking place March 1-4, 2026, in Toronto, Canada. PDAC 2026 Booth Details:Date: March 3-4, 2026Location: Metro Toronto Convention Centre, Toronto, Ontar ...

Core Viewpoint - Laureate Education, Inc. reported strong financial performance for 2025, with significant revenue growth and margin expansion, while also increasing its share repurchase authorization by $150 million to a total of $400 million [1][4][13]. Financial Performance Highlights Fourth Quarter 2025 - Reported revenue was $541.4 million, an increase of $118.0 million or 28% compared to Q4 2024; organic constant currency revenue increased by 16% [5][6]. - Operating income rose to $179.5 million from $124.2 million in Q4 2024, an increase of $55.3 million [5][6]. - Net income for Q4 2025 was $171.5 million, up from $93.6 million in Q4 2024, reflecting an increase of $77.9 million [5][6]. - Basic and diluted earnings per share were $1.18 and $1.17, respectively [5][6]. Year Ended December 31, 2025 - Total revenue for the year was $1,701.9 million, a 9% increase from $1,566.6 million in 2024; organic constant currency revenue increased by 8% [9][10]. - Operating income for 2025 was $431.1 million, compared to $374.0 million in 2024 [9][10]. - Net income decreased to $283.8 million from $296.4 million in 2024, primarily due to foreign currency exchange rate impacts [9][10]. - Adjusted EBITDA for 2025 was $518.9 million, up from $450.1 million in 2024 [10]. Enrollment Metrics - New enrollments for FY 2025 increased by 8% compared to FY 2024, with total enrollments up by 5% [8][9]. - In Peru, new enrollments increased by 13% and total enrollments by 7%; in Mexico, new enrollments rose by 5% and total enrollments by 4% [8]. Balance Sheet and Cash Flow - As of December 31, 2025, Laureate had $146.7 million in cash and cash equivalents, with gross debt of $129.1 million, resulting in net cash of $17.6 million [11]. - The company repurchased approximately $217 million of its common stock during 2025, with $31 million remaining under the previous repurchase authorization [12][13]. Outlook for 2026 - For FY 2026, Laureate expects total enrollments to be between 516,000 and 521,000, reflecting a growth of 4%-5% compared to 2025 [14]. - Revenue is projected to be in the range of $1,890 million to $1,905 million, indicating growth of 11%-12% on a reported basis and 6%-7% on an organic constant currency basis [14].

MONTRÉAL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has issued a notice of redemption (the “Notice of Redemption”) for all of its remaining outstanding 6.000% Senior Notes due 2028, in an aggregate principal amount of US$250,000,000 (the “2028 Notes”). As set forth in the Notice of Redemption, the redemption date is March 6, 2026, and the redemption price for the 2028 Notes is 100% of the principal amount redeemed, plus accrued and unpaid interest. This debt re ...

Financial Performance - For Q4 2025, Navios Partners reported a net income of $117.3 million and EBITDA of $224.8 million, with earnings per common unit at $3.99. For the full year 2025, net income was $285.3 million and EBITDA was $744.6 million, with earnings per common unit at $9.59 [2][5][19]. - Revenue for Q4 2025 was $365.6 million, a 10% increase from $332.5 million in Q4 2024. For the full year, revenue was $1,344.1 million, a slight increase of 0.7% from $1,334.1 million in 2024 [21][26]. Distribution Policy - The company announced a 20% increase in its distribution policy to $0.24 per unit annually, effective from Q1 2026, translating to $0.06 per unit quarterly [2][6][5]. Fleet and Operations - As of February 12, 2026, Navios Partners had repurchased 1,603,713 common units for approximately $72.9 million, with a total of 28,580,675 common units outstanding [3]. - The fleet consists of 67 dry bulk vessels, 51 containerships, and 53 tankers, including 16 newbuilding tankers expected to be delivered through the first half of 2028 [17]. - The company has contracted revenue of $3.8 billion through 2037, with $261 million in new long-term charters expected to generate additional revenue [10][11]. Vessel Transactions - In Q4 2025, Navios Partners acquired two Japanese newbuilding capesize vessels for $134.3 million and agreed to sell two VLCC tankers for $136.5 million [7][8]. - A newbuilding aframax/LR2 tanker was delivered in February 2026, chartered out at a rate of $27,431 net per day for approximately five years [9]. Financial Position - As of December 31, 2025, total assets were $5.93 billion, with total liabilities at $2.59 billion and total partners' capital at $3.34 billion [41]. - Cash and cash equivalents increased to $413.5 million from $312.1 million in 2024 [41]. Market Environment - The company noted that geopolitical tensions and new trade agreements are reshaping trade routes, impacting costs and transit times. This evolving landscape is seen as an opportunity for Navios Partners to leverage its diversified fleet and risk management culture [2].